Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.
作者信息
Özpolat Hasan Tahsin, Stolla Moritz
机构信息
Bloodworks Northwest Research Institute, Seattle, WA, United States of America.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States of America.
出版信息
Blood Transfus. 2023 Sep;21(5):369-374. doi: 10.2450/BloodTransfus.503. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.利妥昔单抗治疗免疫介导的血栓性血小板减少性紫癜
Blood Transfus. 2023 Sep;21(5):369-374. doi: 10.2450/BloodTransfus.503. Epub 2023 Mar 17.
2
Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab.复发性血栓性血小板减少性紫癜经单克隆抗体利妥昔单抗反复治疗成功。
Clin Adv Hematol Oncol. 2006 Mar;4(3):215-7; discussion 217-8.
3
A new treatment strategy for thrombotic thrombocytopenic purpura in developing countries: A single dose rituximab-contained regimen.
Thromb Res. 2022 Dec;220:72-74. doi: 10.1016/j.thromres.2022.10.002. Epub 2022 Oct 7.
4
Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.免疫介导的血栓性血小板减少性紫癜的强化利妥昔单抗方案可避免对标准利妥昔单抗治疗无反应。
Br J Haematol. 2021 Jan;192(1):e21-e25. doi: 10.1111/bjh.17170. Epub 2020 Nov 20.
5
[Rituximab for treatment of immune thrombocytopenia and thrombotic thrombocytopenic purpura].利妥昔单抗治疗免疫性血小板减少症和血栓性血小板减少性紫癜
Rinsho Ketsueki. 2019;60(5):480-487. doi: 10.11406/rinketsu.60.480.
6
Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.硼替佐米，是利妥昔单抗治疗后难治性或复发性血栓性血小板减少性紫癜患者的一种有前景的替代药物。
Br J Haematol. 2022 Nov;199(4):619-622. doi: 10.1111/bjh.18430. Epub 2022 Sep 8.
7
Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.利妥昔单抗治疗慢性复发性血栓性血小板减少性紫癜：1例病例报告及文献复习
Br J Haematol. 2004 Mar;124(6):787-95. doi: 10.1111/j.1365-2141.2004.04836.x.
8
Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism.利妥昔单抗治疗血栓性血小板减少性紫癜合并原发性干燥综合征和原发性甲状腺功能减退症
Intern Med. 2020 Mar 1;59(5):715-719. doi: 10.2169/internalmedicine.3722-19. Epub 2019 Nov 8.
9
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.利妥昔单抗预防血栓性血小板减少性紫癜复发：一例报告
Blood. 2005 Aug 1;106(3):925-8. doi: 10.1182/blood-2004-12-4885. Epub 2005 Apr 12.
10
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.利妥昔单抗治疗与免疫介导的严重ADAMTS13缺乏相关的难治性和/或复发性血栓性血小板减少性紫癜：4例报告及文献系统综述
Eur J Haematol. 2009 Oct;83(4):365-72. doi: 10.1111/j.1600-0609.2009.01292.x. Epub 2009 Jun 8.
引用本文的文献
1
ADAMTS13 in the New Era of TTP.ADAMTS13 在 TTP 的新时代。
Int J Mol Sci. 2024 Jul 26;25(15):8137. doi: 10.3390/ijms25158137.
2
Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group.血栓性血小板减少性紫癜（TTP）的诊断和临床管理：TTP 加泰罗尼亚小组的共识声明。
Blood Transfus. 2024 Mar;22(2):176-184. doi: 10.2450/BloodTransfus.522. Epub 2023 Sep 4.
本文引用的文献
1
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.获得性免疫性血小板减少性紫癜（iTTP）的管理：急性期之后
Ther Adv Hematol. 2022 Jul 26;13:20406207221112217. doi: 10.1177/20406207221112217. eCollection 2022.
2
TTP: From empiricism for an enigmatic disease to targeted molecular therapies.TTP：从对神秘疾病的经验主义到靶向分子治疗。
Br J Haematol. 2022 Apr;197(2):156-170. doi: 10.1111/bjh.18040. Epub 2022 Feb 10.
3
Acquired thrombotic thrombocytopenic Purpura diagnosed during first trimester of pregnancy with excellent outcome after plasma exchange and rituximab, a case report.妊娠期首诊获得性血栓性血小板减少性紫癜，经血浆置换和利妥昔单抗治疗后预后良好：一例报告
Clin Case Rep. 2021 Feb 2;9(3):1304-1306. doi: 10.1002/ccr3.3752. eCollection 2021 Mar.
4
Redefining outcomes in immune TTP: an international working group consensus report.重新定义免疫性血栓性血小板减少性紫癜的结局：国际工作组共识报告。
Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.
5
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.卡泊单抗、免疫抑制和血浆置换联合治疗方案可预防免疫介导的血栓性血小板减少性紫癜的不良结局。
Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.
6
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.国际血栓与止血学会（ISTH）血栓性血小板减少性紫癜治疗指南。
J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.
7
How I treat thrombotic thrombocytopenic purpura in pregnancy.如何治疗妊娠期血栓性血小板减少性紫癜。
Blood. 2020 Nov 5;136(19):2125-2132. doi: 10.1182/blood.2019000962.
8
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.免疫介导性血栓性血小板减少性紫癜缓解期 ADAMTS-13 水平低伴抗 ADAMTS-13 抗体高，高度提示疾病复发：一项多机构研究。
Am J Hematol. 2020 Aug;95(8):953-959. doi: 10.1002/ajh.25845. Epub 2020 May 21.
9
Adjuvant low-dose rituximab and plasma exchange for acquired TTP.辅助性小剂量利妥昔单抗及血浆置换治疗获得性血栓性血小板减少性紫癜
Blood. 2019 Sep 26;134(13):1106-1109. doi: 10.1182/blood.2019000795. Epub 2019 Jul 22.
10
How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.靶向治疗如何打破获得性 TTP 的治疗模式：风险、获益和未知。
Blood. 2019 Aug 1;134(5):415-420. doi: 10.1182/blood.2019000954. Epub 2019 Jun 19.
Zotero 插件